CRITICAL REVIEWS IN IMMUNOLOGY, published by BEGELL HOUSE INC, is an essential journal in the field of immunology that has been contributing to the scientific discourse since 1980. With its ISSN 1040-8401 and E-ISSN 2162-6472, this journal provides a platform for critical analysis and comprehensive reviews that deepen understanding of immune responses and their implications in health and disease. Although currently categorized in the Q4 quartile for Immunology and Q3 for Immunology and Allergy, the journal's quality research and scholarly contributions are crucial for advancing knowledge within its fields—encompassing various aspects of innate and adaptive immunity. Researchers and professionals in immunology will find invaluable insights, aiding them in their quest for innovation and excellence, as the journal aims to foster interdisciplinary collaboration. While it does not operate on an open-access model, CRITICAL REVIEWS IN IMMUNOLOGY remains a significant resource for those dedicated to pushing the boundaries of immunology, with annual publications expected to last well into 2024 and beyond.

JOURNAL OF IMMUNOTHERAPY, published by Lippincott Williams & Wilkins, is a premier journal dedicated to advancing the field of immunotherapy, a vital aspect of contemporary cancer research and treatment. With an ISSN of 1524-9557 and an E-ISSN of 1537-4513, this esteemed journal has been disseminating cutting-edge research since 1991 and continues to thrive with a convergence of knowledge leading into 2024. Recognized in the top Q2 quartile for fields such as Cancer Research, Immunology, and Allergy, as well as achieving a Q1 ranking in Pharmacology, the journal serves as a critical resource for researchers, clinicians, and students alike. Its robust impact is reflected in its competitive Scopus rankings across various categories, where it holds significant percentile standings. Highly regarded in the academic community for its rigor, the JOURNAL OF IMMUNOTHERAPY aims to provide a platform for innovative ideas, clinical findings, and experimental research that propels the science of immunotherapy forward. Although it does not offer open access, the journal ensures that its contents remain accessible and impactful for professionals in the field, fostering collaboration and knowledge exchange in an era where immunotherapy holds the promise for breakthroughs in patient care.

Welcome to the European Journal of Immunology, a premier peer-reviewed journal dedicated to advancing the field of immunology and allergy research. Established in 1971 and published by Wiley, this esteemed journal has been consistently ranked in the top quartile (Q1) across its categories, highlighting its significant impact within the scientific community. With an impressive Scopus ranking, the journal occupies the 64th position in Immunology and Allergy and the 74th in the broader sector of Immunology and Microbiology, demonstrating its vital role in driving innovation and knowledge in immunological studies. The European Journal of Immunology publishes high-quality original research, comprehensive reviews, and insightful commentary, making it an indispensable resource for researchers, healthcare professionals, and students dedicated to understanding the complexities of the immune system. Although not an open-access journal, it offers various subscription options to ensure that institutions and individuals can access pivotal research that shapes the future of immunology.

Cancer Cell, published by Cell Press, represents a pinnacle of research in the fields of cancer research, cell biology, and oncology. With an impressive Impact Factor and ranking as Q1 in prestigious categories for both 2023 and previous years, this journal stands out as a vital resource for professionals and scholars dedicated to understanding the molecular underpinnings of cancer. Operating from Cambridge, MA, Cancer Cell has been an essential platform for innovative studies since its inception in 2002. Although it is not an Open Access journal, its rigorous peer-review process ensures that only the highest quality research is disseminated to the scientific community. Readers can expect to find a wealth of knowledge ranging from cutting-edge therapies to insights into tumor biology, thereby contributing significantly to the advancement of oncology. With rankings placing it among the top echelons of related fields—#2 in Cancer Research and #6 in Oncology—Cancer Cell is an indispensable reference for anyone committed to the fight against cancer.

IMMUOLOGY LETTERS, published by Elsevier, is a distinguished journal in the field of immunology, focusing on the latest advancements and findings that significantly influence immunological research and clinical applications. Established in 1979, the journal has evolved to cater to a global readership, featuring high-quality peer-reviewed articles across a diverse spectrum of topics related to immunity and allergic responses. With an impressive Q2 category ranking in both Immunology and Allergy as of 2023, it holds a strong position within the scientific community, evidenced by its commendable Scopus rankings (Rank #71/233 in Medicine - Immunology and Allergy and Rank #85/236 in Immunology and Microbiology - Immunology). While primarily subscription-based, the journal aims to foster knowledge dissemination that encourages collaboration among researchers and practitioners alike, making significant contributions to the understanding of immune mechanisms. The journal is integral for educators, students, and professionals aiming to stay abreast of current trends and breakthroughs in the immune system's intricate functions.

OncoImmunology is a leading peer-reviewed journal published by Taylor & Francis Inc, dedicated to advancing the understanding of the dynamic interplay between the immune system and cancer. Established in 2012 and adopting an open access model since 2020, OncoImmunology provides a platform for high-quality research disseminated globally, with a notable focus on innovative therapies and immunotherapeutic strategies aimed at improving patient outcomes. The journal boasts an impressive impact in the field, holding Q1 rankings in both Immunology and Oncology categories for 2023, and it is recognized within the top-tier journals in its domain, reflected in its Scopus ranks and percentiles. With contributions from leading experts and a wide audience of researchers, clinicians, and advanced students, OncoImmunology not only facilitates scholarly dialogue but also addresses pivotal challenges in cancer treatment, making it an essential resource for those invested in the future of oncological and immunological research.

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

Molecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

ImmunoTargets and Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of immunology and its various therapeutic applications. Since its inception in 2012, the journal has rapidly become a vital resource for researchers, professionals, and students, achieving notable recognition with a Q1 ranking in both Immunology and Immunology and Allergy categories as of 2023. With an impressive Scopus ranking of #22 out of 233 in Medicine - Immunology and Allergy, and #25 out of 236 in Immunology and Microbiology, this journal maintains a 90th percentile standing in its field. ImmunoTargets and Therapy not only publishes original research articles, reviews, and clinical studies, but also fosters an inclusive platform for the dissemination of innovative findings critical to the fight against immunological disorders. Based in New Zealand, it serves a global audience, promoting knowledge exchange and collaboration through its open access model.